The American Oncology Network, LLC, has added 5 medical oncologists to its Executive Committee.
With a mission to support the long-term viability of community oncology, the American Oncology Network, LLC (AON) has named medical oncologist Stephen “Fred” Divers, MD, from the Genesis Cancer Center in Arkansas, as the new advisory board chair. The AON Advisory Board provides strategic guidance to its growing network of physicians and practices, currently in 13 states.
Divers has provided physician leadership as a member of several national committees and currently serves on the Board of Directors for the Community Oncology Alliance. He attended medical school at the Louisiana State University School of Medicine. He completed his residency at the University of North Carolina and a fellowship at the University of Alabama at Birmingham Cancer Center.
Additionally, Michael J. Castine, III, MD, from the Hematology/Oncology Clinic in Louisiana; Patrick C. Elwood, MD, and Taral Patel, MD, from the Zangmeister Cancer Center in Ohio; and Rangappa Rajendra, MD, from Oncology/Hematology of Loudoun and Reston in Virginia were named to the Executive Committee. The 5 medical oncologists represent the inaugural group members appointed in April 2020.
Consisting of 18 physicians representing AON’s rapidly expanding network, the group advises on a range of trends impacting clinical and practice activities. The group’s goal is to serve as an advocate for AON’s physicians and physician groups, providing counsel and support on all issues related to business improvement, strategic development, quality, and compliance.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More